Bavarian Nordic Realigns for Expansion

Creation of two business divisions: Cancer Vaccines and Infectious Diseases

05-Oct-2010 - Denmark

Bavarian Nordic A/S announced the reorganization of the company's primary business areas into two divisions; Cancer vaccines and infectious diseases each led by its own Division President reporting to the President & CEO of the Company. The establishment of two divisions facilitates a stronger and more effective management structure and offers a number of benefits to the company, including: optimization of resource management and investments, acceleration of development and in-licensing of new products within cancer and infectious diseases and multiple funding options and separate strategic partnership opportunities

Reiner Laus, Executive Vice President and CEO of BN ImmunoTherapeutics, Inc., Bavarian Nordic's wholly-owned cancer research unit in California, USA has been appointed Division President Cancer Vaccines. The division's main short-term strategic objectives are driving PROSTVAC(TM) to the market through partnership, broadening the portfolio by acquisitions and developing new cancer targets.

Paul Chaplin, Executive Vice President and Chief Scientific Officer, has been appointed Division President Infectious Diseases. The division's main short-term strategic objectives are the continued delivery of IMVAMUNE® under the contract with the US government, while also securing new IMVAMUNE® orders and developing new late-stage vaccine candidates for infectious diseases beyond biodefence, supported by partnerships and/or acquisitions.

VaxEquity Announces Strategic Collaboration with AstraZeneca to Commercialise Self-Amplifying RNA Platform

VaxEquity receives upfront equity investment and up to $195 million and royalties in the mid-single digits per programme

Read news

In order to provide strong leadership and accountability within the new structure, the executive management will be consolidated. As a consequence, Executive Vice President Steen Vangsgaard & Executive Vice President Anders Gram will be leaving Bavarian Nordic. Morten M. Rasmussen will continue as Senior Vice President, Legal/IP reporting to Anders Hedegaard. The executive management team hereafter consists of:

- Anders Hedegaard, President & CEO

- Paul Chaplin, Executive Vice President and Division President Infectious Diseases

- Reiner Laus, Executive Vice President and Division President Cancer Vaccines

- Ole Larsen, Executive Vice President and Chief Financial Officer

https://www.bionity.com/en/news/123815/bavarian-nordic-realigns-for-expansion.html